Arcus Biosciences, Inc. Increase (Decrease) in Contract with Customer, Liability
Arcus Biosciences, Inc. (RCUS) reported Increase (Decrease) in Contract with Customer, Liability of -$54.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$37.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$17.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$26.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$26.00M, a 138.81% decline year-over-year.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$240.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$56.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$68.00M.
- Arcus Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$112.00M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 6 month as first filed | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$37.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$54.00M 10-Q · filed 2026-08-05 | -$80.00M derived: sum of 3 quarters · filed 2026-08-05 | -$106.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$17.00M 10-Q · filed 2026-05-05 | -$43.00M derived: sum of 2 quarters · filed 2026-05-05 | -$69.00M derived: sum of 3 quarters · filed 2026-05-05 | -$229.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$26.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$52.00M derived: sum of 2 quarters · filed 2026-02-25 | -$212.00M derived: sum of 3 quarters · filed 2026-08-05 | -$240.00M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | -$26.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$186.00M derived: sum of 2 quarters · filed 2026-08-05 | -$214.00M 10-Q · filed 2025-10-28 | -$256.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$160.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$188.00M 10-Q · filed 2026-08-05 | -$230.00M derived: sum of 3 quarters · filed 2026-08-05 | -$163.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$28.00M 10-Q · filed 2026-05-05 | -$70.00M derived: sum of 2 quarters · filed 2026-05-05 | -$3.00M derived: sum of 3 quarters · filed 2026-05-05 | -$42.00M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $25.00M derived: sum of 2 quarters · filed 2026-02-25 | -$14.00M derived: sum of 3 quarters · filed 2026-02-25 | -$56.00M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $67.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $28.00M derived: sum of 2 quarters · filed 2025-10-28 | -$14.00M 10-Q · filed 2025-10-28 | -$31.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | -$39.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$81.00M 10-Q · filed 2025-08-06 | -$98.00M derived: sum of 3 quarters · filed 2026-02-25 | -$130.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | -$42.00M 10-Q · filed 2025-05-06 | -$59.00M derived: sum of 2 quarters · filed 2026-02-25 | -$91.00M derived: sum of 3 quarters · filed 2026-02-25 | -$85.00M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | -$17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$49.00M derived: sum of 2 quarters · filed 2026-02-25 | -$43.00M derived: sum of 3 quarters · filed 2026-02-25 | -$68.00M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | -$32.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$26.00M derived: sum of 2 quarters · filed 2024-11-06 | -$51.00M 10-Q · filed 2024-11-06 | -$85.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$19.00M 10-Q · filed 2024-08-08 | -$53.00M derived: sum of 3 quarters · filed 2025-02-25 | -$86.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | -$25.00M 10-Q · filed 2024-05-08 | -$59.00M derived: sum of 2 quarters · filed 2025-02-25 | -$92.00M derived: sum of 3 quarters · filed 2025-02-25 | -$119.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | -$34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$67.00M derived: sum of 2 quarters · filed 2025-02-25 | -$94.00M derived: sum of 3 quarters · filed 2025-02-25 | -$112.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | -$33.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$60.00M derived: sum of 2 quarters · filed 2023-11-07 | -$78.00M 10-Q · filed 2023-11-07 | -$78.34M 10-Q · filed 2022-11-02 | -$417.62M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | -$27.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$45.00M 10-Q · filed 2023-08-07 | -$44.76M 10-Q · filed 2022-08-03 | -$384.62M derived: sum of 3 quarters · filed 2024-02-21 | -$394.08M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | -$18.00M 10-Q · filed 2023-05-09 | -$18.00M 10-Q · filed 2022-05-09 | -$357.62M derived: sum of 2 quarters · filed 2024-02-21 | -$367.08M derived: sum of 3 quarters · filed 2024-02-21 | -$376.54M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | -$339.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$349.08M derived: sum of 2 quarters · filed 2024-02-21 | -$358.54M derived: sum of 3 quarters · filed 2024-02-21 | -$368.00M 10-K · filed 2024-02-21 | -$367.88M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | -$9.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$18.92M derived: sum of 2 quarters · filed 2022-11-02 | -$28.38M 10-Q · filed 2022-11-02 | -$28.27M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-06-30 | -$9.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$18.92M 10-Q · filed 2022-08-03 | -$18.81M derived: sum of 3 quarters · filed 2023-02-28 | $172.58M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | -$9.46M 10-Q · filed 2022-05-09 | -$9.35M derived: sum of 2 quarters · filed 2023-02-28 | $182.04M derived: sum of 3 quarters · filed 2023-02-28 | $180.29M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $191.50M derived: sum of 2 quarters · filed 2023-02-28 | $189.75M derived: sum of 3 quarters · filed 2023-02-28 | $188.00M 10-K · filed 2023-02-28 | $178.38M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $191.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $189.64M derived: sum of 2 quarters · filed 2021-11-08 | $187.89M 10-Q · filed 2021-11-08 | $186.14M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | -$1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$3.50M 10-Q · filed 2021-08-05 | -$5.25M derived: sum of 3 quarters · filed 2022-02-23 | -$2.00M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | -$1.75M 10-Q · filed 2021-05-05 | -$3.50M derived: sum of 2 quarters · filed 2022-02-23 | -$250.00K derived: sum of 3 quarters · filed 2022-02-23 | -$2.00M derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | -$1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $1.50M derived: sum of 2 quarters · filed 2022-02-23 | -$250.00K derived: sum of 3 quarters · filed 2022-02-23 | -$2.00M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | $3.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.50M derived: sum of 2 quarters · filed 2020-11-05 | -$250.00K 10-Q · filed 2020-11-05 | -$1.81M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | -$1.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$3.50M 10-Q · filed 2020-08-06 | -$5.06M derived: sum of 3 quarters · filed 2021-02-25 | -$1.35M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$1.75M 10-Q · filed 2020-05-05 | -$3.31M derived: sum of 2 quarters · filed 2021-02-25 | $397.00K derived: sum of 3 quarters · filed 2021-02-25 | -$853.00K derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.15M derived: sum of 2 quarters · filed 2021-02-25 | $897.00K derived: sum of 3 quarters · filed 2021-02-25 | -$353.00K 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $3.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $2.46M derived: sum of 2 quarters · filed 2019-11-05 | $1.21M 10-Q · filed 2019-11-05 | |||||
| 2018-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$2.50M 10-Q · filed 2019-08-06 | ||||||
| 2018-03-31 | -$1.25M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |